D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$751M |
| 2 |
Advanced Micro Devices
AMD
|
+$751M |
| 3 |
Micron Technology
MU
|
+$426M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$363M |
| 5 |
ExxonMobil
XOM
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$546M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$485M |
| 3 |
VMW
VMware, Inc
VMW
|
+$393M |
| 4 |
Microsoft
MSFT
|
+$336M |
| 5 |
UnitedHealth
UNH
|
+$303M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.03% |
| 2 | Consumer Discretionary | 9.51% |
| 3 | Healthcare | 5.76% |
| 4 | Financials | 5.47% |
| 5 | Communication Services | 4.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
PUT
Iron Mountain
IRM
$37.4B
| $4.14M | ﹤0.01% |
59,100
+32,500
| +122% | +$2.04M |
|
1927
PUT
Zillow
ZG
$7.74B
| $4.11M | ﹤0.01% |
72,500
| – | – |
|
1928
Petco
WOOF
$811M
| $4.11M | ﹤0.01% |
1,299,808
+922,170
| +244% | +$3.19M |
|
1929
Fortive
FTV
$19.5B
| $4.09M | ﹤0.01% |
73,715
-124,726
| -63% | -$6.58M |
|
1930
CALL
State Street
STT
$50.2B
| $4.09M | ﹤0.01% |
+52,800
| New | +$3.68M |
|
|
ANSS
1931
DELISTED
Ansys
ANSS
| $4.09M | ﹤0.01% |
11,258
+1,383
| +14% | +$410K |
|
1932
CALL
Cenovus Energy
CVE
$51.6B
| $4.08M | ﹤0.01% |
245,000
| – | – |
|
1933
Cellebrite
CLBT
$3.7B
| $4.08M | ﹤0.01% |
471,108
+315,488
| +203% | +$2.45M |
|
1934
PUT
TKO Group
TKO
$13.9B
| $4.08M | ﹤0.01% |
+50,000
| New | +$3.97M |
|
1935
Ramaco Resources Class A
METC
$637M
| $4.08M | ﹤0.01% |
+245,288
| New | +$3.4M |
|
1936
Eldorado Gold
EGO
$8.4B
| $4.08M | ﹤0.01% |
314,285
+283,735
| +929% | +$3.19M |
|
1937
PUT
Hasbro
HAS
$13.6B
| $4.07M | ﹤0.01% |
79,800
+75,900
| +1,946% | +$3.83M |
|
|
NVO
1938
Novo Nordisk
NVO
$225B
| $4.07M | ﹤0.01% |
39,297
-7,033
| -15% | -$696K |
|
|
FOLD
1939
DELISTED
Amicus Therapeutics
FOLD
| $4.06M | ﹤0.01% |
286,224
-73,967
| -21% | -$840K |
|
1940
PUT
SM Energy
SM
$7.11B
| $4.06M | ﹤0.01% |
104,800
-7,600
| -7% | -$293K |
|
1941
CALL
Gilead Sciences
GILD
$167B
| $4.05M | ﹤0.01% |
50,000
-200
| -0.4% | -$15.6K |
|
|
ETWO
1942
DELISTED
E2open Parent Holdings
ETWO
| $4.04M | ﹤0.01% |
921,032
+882,352
| +2,281% | +$3.13M |
|
1943
Amneal Pharmaceuticals
AMRX
$5.99B
| $4.04M | ﹤0.01% |
666,036
-208,880
| -24% | -$930K |
|
1944
Cabot Corp
CBT
$4.7B
| $4.04M | ﹤0.01% |
48,406
+31,499
| +186% | +$2.34M |
|
1945
GoodRx Holdings
GDRX
$1.06B
| $4.04M | ﹤0.01% |
602,767
+122,985
| +26% | +$693K |
|
1946
CALL
Illumina
ILMN
$29.2B
| $4.04M | ﹤0.01% |
29,812
+10,280
| +53% | +$1.19M |
|
1947
PUT
Tandem Diabetes Care
TNDM
$1.22B
| $4.04M | ﹤0.01% |
136,500
+106,500
| +355% | +$2.21M |
|
|
SEM
1948
DELISTED
Select Medical
SEM
| $4.02M | ﹤0.01% |
317,716
+256,446
| +419% | +$3.24M |
|
1949
Hercules Capital
HTGC
$3.04B
| $4.02M | ﹤0.01% |
240,996
+95,888
| +66% | +$1.52M |
|
1950
Core Laboratories
CLB
$493M
| $4.02M | ﹤0.01% |
227,442
+26,115
| +13% | +$526K |
|
Similar funds
D.E. Shaw & Co's Q4 2023 Portfolio in Review
As of Q4 2023, D.E. Shaw & Co held 4,806 positions worth $114B, up 19% from $95.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
D.E. Shaw & Co's Q4 2023 filing shows 575 new, 1,549 increased, 1,464 reduced and 527 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $546M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- D.E. Shaw & Co's largest Q4 2023 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M.
- D.E. Shaw & Co added most to Netflix in Q4 2023, an estimated $751M increase.
- D.E. Shaw & Co's biggest Q4 2023 reduction was Microsoft, cutting an estimated $336M.
- D.E. Shaw & Co fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $546M.
- D.E. Shaw & Co's ten largest holdings make up 12% of its $114B portfolio in Q4 2023.
- D.E. Shaw & Co opened 575 new positions and closed 527 in Q4 2023.
- D.E. Shaw & Co's portfolio value rose 19% quarter-over-quarter to $114B.
Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.